Novo Nordisk Wegovy Pill Shows Sustained Weight Loss

Novo Nordisk's oral semaglutide pill, marketed as Wegovy for weight loss, has demonstrated sustained weight reduction in patients who transitioned from the injectable formulation. A real-world study, published in The Lancet Gastroenterology & Hepatology, analyzed data from over 30,000 individuals in the United States who were prescribed either the Wegovy injection or the oral semaglutide pill between January 2022 and March 2024. The findings suggest that the oral formulation is a viable alternative for long-term weight management, potentially offering greater convenience for patients.

The study specifically focused on patients who switched from the weekly subcutaneous injection of semaglutide to the daily oral pill. These patients maintained a significant proportion of their initial weight loss, with an average reduction of 10.7% of their body weight after one year on the oral treatment. This contrasts with the 12.4% average weight loss observed in patients who continued with the injectable Wegovy. The difference of 1.7% is considered clinically insignificant by many experts, indicating that the oral pill effectively supports ongoing weight loss maintenance.

Novo Nordisk, a Danish pharmaceutical company renowned for its diabetes and obesity treatments, developed both the injectable and oral versions of semaglutide. The injectable Wegovy (2.4 mg weekly) received FDA approval in June 2021 for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity. The oral semaglutide pill, also known as Rybelsus when used for type 2 diabetes and being explored for weight management, offers a daily dosing regimen. This study provides crucial real-world evidence supporting the efficacy of the oral option for patients seeking less frequent administration compared to weekly injections.

Researchers observed that the adherence rates for the oral pill were comparable to those for the injectable medication, suggesting that patient preference for convenience does not necessarily translate to lower compliance. The study's lead author, Dr. John Deanfield, a professor of cardiology at University College London, stated that the results are "reassuring" for patients and clinicians considering the switch. The implications of these findings are significant for the obesity treatment landscape, potentially broadening access to effective weight management solutions and improving patient adherence to long-term therapy. Novo Nordisk has been a dominant player in the GLP-1 receptor agonist market, with semaglutide-based products like Ozempic (for type 2 diabetes) and Wegovy driving substantial revenue growth for the company.